Clinical trials
Choroidal Neovascularization clinical trials
Below are recruiting choroidal neovascularization clinical trials, each written for real people, not researchers. We’re tracking 7 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04439708Recruiting
Biomarkers for abnormal eye blood vessels
This study is looking for biomarkers (clues in your body) related to abnormal blood vessels in the eye. It may help researchers understand and treat conditions like macular degeneration.
ParisAges 18–90 - NCT06742307RecruitingPhase 4
Faricimab quarterly shots for wet age-related macular degeneration
This trial tests if faricimab eye injections given every 3 months can keep wet age-related macular degeneration under control. It is for people with a new or returning active blood vessel growth in the center of the macula.
Hong KongAges 50 years+ - NCT07695207RecruitingPhase 3
Testing SMZ1 with ranibizumab for wet macular degeneration
This trial tests a new medicine called SMZ1 combined with ranibizumab (a standard treatment) for people with wet macular degeneration. It may help improve vision by targeting the cause of the disease more effectively.
Seoul, SeoulAges 50 years+ - NCT07440225RecruitingPhase 2/Phase 3
Testing a new drug for wet macular degeneration
This trial tests a new medicine called EYE201/MK-8748 for people who have wet age-related macular degeneration (a condition where abnormal blood vessels grow under the retina). It's for those who haven't had treatment before and were diagnosed recently.
Scottsdale, ArizonaAges 50 years+ - NCT07496567RecruitingPhase 2/Phase 3
Study of EYE201 for wet age-related macular degeneration
This trial tests a new medicine, EYE201, for people with wet age-related macular degeneration (AMD) that has not been treated before. The study will see if this drug can help improve vision and slow down vision loss.
Gilbert, ArizonaAges 50 years+ - NCT07695298RecruitingPhase 4
Testing faricimab for a rare eye disease linked to histoplasmosis
This trial tests a drug called faricimab (brand name Vabysmo) for treating abnormal blood vessel growth in the back of the eye, caused by a past infection with histoplasmosis. The goal is to see if it helps improve vision over 52 weeks.
Cincinnati, OhioAges 18 years+ - NCT07002372Recruiting
Watching a video before your first eye injection
This study tests whether watching a short video before your first eye injection helps you feel more at ease. It is for people who have never had this injection before.
Hangzhou, ZhejiangAges 18 years+
Hear when a new Choroidal Neovascularization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for choroidal neovascularization?
- Yes. Clin2 currently lists 7 recruiting choroidal neovascularization studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a choroidal neovascularization trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a choroidal neovascularization trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.